Original ArticlesCOVID-19 Diagnostic Testing and ChallengesOgbebor, Osakpolor MD; Min, Zaw MD, FACP, FIDSA; Cheema, Tariq MD, FCCP, MMM; Bhanot, Nitin MD, MPH, FIDSAAuthor Information Divisions of Infectious Disease (Drs Ogbebor and Min) and Pulmonary Critical Care (Drs Cheema and Bhanot), Allegheny General Hospital, Allegheny Health Network, Pittsburgh, Pennsylvania. Correspondence: Osakpolor Ogbebor, MD, Division of Infectious Disease, Allegheny General Hospital, Allegheny Health Network, 320 East North Ave, Pittsburgh, PA 15212 ([email protected]). Conflict of Interest: Tariq Cheema serves on speaker's bureau for GlaxoSmithKline and Boehringer Ingelheim, GSK. Nitin Bhanot received one-time honorarium to attend an advisory meeting by the MicrogenDx Company. For Osakpolor Ogbebor, MD, and Zaw Min, MD, none declared. Critical Care Nursing Quarterly: October/December 2020 - Volume 43 - Issue 4 - p 343-348 doi: 10.1097/CNQ.0000000000000320 Buy Metrics Abstract Coronavirus disease-2019 (COVID-19) was declared a pandemic by the World Health Organization on March 11, 2020. Following this, there has been a rapid development in policies and strategies to contain and mitigate the pandemic. One of such strategies involves the development and utilization of testing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative organism of COVID-19. In this article, we explore the diagnostic modalities for COVID-19 based on the available information to date. © 2020 Wolters Kluwer Health, Inc. All rights reserved.